A case report of a patient with rheumatoid arthritis complicated with Mycobacterium avium during tocilizumab treatment

References

• Harris ED Jr. Rheumatoid arthritis. Pathophysiology and impli-cations for therapy. N Engl J Med. 1990;322:1277–89.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab mono-therapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12–9.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20:222–32.
   Google Scholar
• Benson CA, Ellner JJ. Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clin Infect Dis. 1993;17:7–20.
   PubMed Web of Science ®Google Scholar
• Okubo H, Iwamoto M, Yoshio T, Okazaki H, Bandoh M, Minota S. Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab. Mod Rheum. 2005;15:62–4.
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30:1426–35.
   Google Scholar
• Horsburgh CR. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med. 1991; 324:1332–8.
   PubMed Web of Science ®Google Scholar
• Opravil M. Epidemiological and clinical aspects of mycobacterial infections. Infection. 1997;25:56–9.
   PubMed Web of Science ®Google Scholar
• Medical Section of the American Lung Association. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156(2 pt 2):S1–25.
   Google Scholar
• Hsu N, Young LS, Bermudez LE. Response to stimulation with recombinant cytokines and synthesis of cytokines by murine intestinal macrophages infected with the Mycobacterium avium complex. Infect Immun. 1995;63:528–33.
   Google Scholar
• Jacobs M, Togbe D, Fremond C, Samarina A, Allie N, Botha T, et al. Tumor necrosis factor is critical to control tuberculosis infection. Microbes Infect. 2007;9:623–8.
   PubMed Web of Science ®Google Scholar
• Appelberg R, Castro AG, Pedrosa J, Silva RA, Orme IM, et al. Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of Mycobacterium avium infection. Infect Immun. 1994;62:3962–71.
   PubMedGoogle Scholar
• Gomez-Flores R, Tucker SD, Kansa' R, Tamez-Guerra R, Mehta RT. Enhancement of antibacterial activity of clofazimine against Mycobacterium avium-Mycobacterium intracellulare complex infection induced by IFN-y is mediated by TNF-a. J Antimicrob Chemother. 1997;39:189–97.
   Google Scholar
• Bekker LG, Freeman S, Murray PJ, Ryffel B, Kaplan G. TNF-a controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide syn-thase-independent pathways. J Immunol. 2001;166:6728–34.
   Google Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with inflix-imab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.
   Google Scholar
• Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to signifi-cant increase in tuberculosis risk: a multicenter active-surveil-lance report. Arthritis Rheum. 2003;48:2122–7.
   Google Scholar
• Ehlers S. Tumor necrosis factor and its blockade in granuloma-tous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis. 2005;41(Suppl 3):5199–203.
   Google Scholar
• Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Us-tianowski A. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522–8.
   Google Scholar
• Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun. 2001;69:1847–55.
   PubMed Web of Science ®Google Scholar
• Ogata A, Mori M, Hashimoto S, Yano Y, Fujikawa T, Kawai M, et al. Minimal influence of tocilizumab on IFN-y synthesis by tuberculosis antigens. Mod Rheumatol. 2010;20:130–3.
   PubMed Web of Science ®Google Scholar
• Tomioka H, Maw WW, Sato K, Sato H. The role of tumour necrosis factor-a in combination with interferon-y or interleukin-1 in the induction of immunosuppressive macrophages because of Mycobacterium avium complex infection. Immunology. 1996;88: 61–7.
   PubMed Web of Science ®Google Scholar
• Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2006;65:1661–3.
   PubMed Web of Science ®Google Scholar
• Klebanoff SJ, Vadas MA, Harlan JM, Sparks LH, Gamble JR, Agosti JM, et al. Stimulation of neutrophils by tumor necrosis factor. J Immunol. 1986;136:4220–5.
   PubMed Web of Science ®Google Scholar
• Neumann B, Machleidt T, Lifka A, Pfeffer K, Vestweber D, Mak TW, et al. Crucial role of 55-kilodalton TNF receptor in TNF-induced adhesion molecule expression and leukocyte organ infiltration. J Immunol. 1996;156:1587–93.
   PubMed Web of Science ®Google Scholar
• Nakamatsu M, Yamamoto N, Hata M, Nakasone C, Kinjo T, Miyagi K, et al. Role of interferon-gamma in Valphal4+ natural killer T cell-mediated host defense against Streptococcus pneu-moniae infection in murine lungs. Microbes Infect. 2007;9:364–74.
   PubMedGoogle Scholar
• Ruan S, Young E, Luce MJ, Reiser J, Kolls JK, Shellito JE. Conditional expression of interferon-gamma to enhance host responses to pulmonary bacterial infection. Pulm Pharmacol 'Ther. 2006;19:251–7.
   PubMed Web of Science ®Google Scholar
• Sutherland RE, Olsen JS, McKinstry A, Villalta SA, Wolters PJ. Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol. 2008;181: 5598–605.
   Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Post-marketing surveillance program of tocilizumab for RA in Japan-interim analyses of 3,881 patients. Arthritis Rheum. 2010;62(10):5168.
   Google Scholar
• Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898–906.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Japanese MRA Study Group for RA. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis at recurrence (RESTORE study). Ann Rheum Dis. 2010;69(Suppl 3):537.
   Google Scholar